Brentuximab vedotin: clinical updates and practical guidance
نویسندگان
چکیده
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.
منابع مشابه
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
BACKGROUND Recently, brentuximab vedotin has become a promising therapeutic approach for CD30-positive hematological malignancies, but its role in other relapsed or refractory malignant lymphoma needs to be proven. Brentuximab vedotin was demonstrated effective, but no study has summarized the concrete effect of brentuximab vedotin in malignant lymphoma. To truly know the role of brentuximab ve...
متن کاملBrentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
Brentuximab vedotin is a promising antibody-drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refractory Hodgkin's lymphoma (HL), and it has also shown its advantages in other CD30-positive lympho...
متن کاملHighlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition.
SUMMARY Three-Year Survival Results From an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Updated survival results were presented from a multicenter, open-label, phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic ALCL (Abstract 1809). The trial had enrolled 58 patients, with a media...
متن کاملBlood Spotlight Brentuximab vedotin
Delivery of cytotoxic agents specifically to malignant cells has always been a goal of cancer therapy. With the development of monoclonal antibodies for clinical use, this goal has become a reality, and antibody-drug conjugates are now part of standard therapy in diseases such as lymphoma and breast cancer. Brentuximab vedotin, which targets CD30, has contributed to the success of antibody-drug...
متن کاملMultiple successful desensitizations to brentuximab vedotin: a case report and literature review.
Brentuximab vedotin is an antibody-drug conjugate FDA-approved for the treatment of systemic anaplastic large-cell lymphoma (ALCL) that has relapsed after multiagent chemotherapy. At least 2 cases of hypersensitivity reactions to brentuximab vedotin have been reported, without attempted desensitization. This report describes a morbidly obese 32-year-old woman with ALCL that relapsed after autol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 52 شماره
صفحات -
تاریخ انتشار 2017